Companies: 10,795·Total market cap: $144.5T
RedHill Biopharma Ltd.

RedHill Biopharma Ltd.

RDHLNASDAQHealthcare● Active
$0.88
$-0.15(-14.22%)
Market Cap$2750000
P/E Ratio—
52W High$3.31
52W Low$0.71
Overview
Foreign Private Issuer · Files 20-F / 6-K

RedHill Biopharma Ltd. (RDHL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001553846 · RDHL · NASDAQ · as of Jun 10, 2026

Filing snapshot

1,000+
Total Filings
6-K
Latest Form
2026-06-09
Most Recent
2013
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001553846 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-04-27
Fiscal Year End
Apr 27, 2026
Accession No.
0001104659-26-049055
Primary Document
rdhl-20251231x20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001553846 · Accession 0001104659-26-049055

Latest Key Filings

6-KQuarterly Report
6-K
2026-06-09
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-09
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-08
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-02
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-27
View
424B5424B5
424B5
2026-05-07
View
EFFECTEFFECT
EFFECT
2026-05-05
View
POS AMPOS AM
POS AM
2026-05-04
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-30
View
20-FAnnual Report (Foreign Issuer)
20-F
2026-04-27
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-27
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-22
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-19
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
Showing 1–15 of 999 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001553846  |  Exchange: NASDAQ · Healthcare

RedHill Biopharma Ltd. (NASDAQ: RDHL) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001553846, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is RedHill Biopharma Ltd.'s most comprehensive regulatory disclosure. The most recent RedHill Biopharma Ltd. 10-K was filed on 2026-04-27 for fiscal year ending 2026. Historical RDHL 10-K annual reports are available from 2012 through 2026.

Investors researching RedHill Biopharma Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
FLGC SEC Filings →CNSP SEC Filings →BGMS SEC Filings →SXTP SEC Filings →IMCC SEC Filings →BNBX SEC Filings →AKAN SEC Filings →GCTK SEC Filings →
→ RDHL Financials→ RDHL Earnings→ RDHL Insider Trades

Frequently Asked Questions

RDHL SEC Filings · 8 questions

RedHill Biopharma Ltd. (RDHL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. RedHill Biopharma Ltd.'s CIK is 0001553846.

RDHL SEC filingsRedHill Biopharma Ltd. SEC documentsfind RDHL 10-K